Aykut Karahan | Istock | Getty Images A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox. Subscribe here to receive future editions. Happy Friday! Buried in the election news this week was new data from drugmakers vying to enter the booming weight loss drug market. Pharmaceutical giant AstraZeneca and biotech company Viking Therapeutics were among the companies that presented encouraging data on their obesity pills an ...

The latest trading session saw Astrazeneca (AZN) ending at $64.69, denoting a +1.32% adjustment from its last day's close. The stock outpaced the S&P 500's daily gain of 0.74%.The the stock of pharmaceutical has fallen by 17.62% in the past month, lagging the Medical sector's loss of 2.99% and the S&P 500's gain of 3.16%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on November ...

When I last wrote about the Anglo-Swedish pharmaceuticals company AstraZeneca (NASDAQ: AZN ) in June, further upside to the stock was already unlikely. This prompted a Hold rating on it, breaking the trend from the previous seven Buy ratings on it since 2022. This Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gree ...

Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $1.01 per share in its upcoming report, which indicates a year-over-year increase of 16.1%. Revenues are expected to be $13.04 billion, up 13.5% from the year-ago quarter. The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before ...

Key TakeawaysZacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture appears to brighten in 2025.The healthcare company has beaten earnings estimates in three of the past four quarters.Register now to see our 7 Best Stocks for the Next 30 Days report - free today!AstraZeneca (AZN) will report its third-quarter earnings on Nov. 12, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.04 billion and $1.01 per share, respectiv ...

Company News - AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an insurance fraud case [1] - AstraZeneca China President Leon Wang is cooperating with Chinese authorities [1] - In September, five current and former AstraZeneca employees were detained by police in China in connection with multiple investigations [1] - Dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case [2] - The company stated that if requested, it will fully cooperate with the Chinese authorities [2] - Five current and former AstraZeneca employees were detained by police in China in September in connection with alleged violations of data privacy laws and for importing an unapproved cancer drug [3] - AstraZeneca employs roughly 16,000 workers in China and has operated there since 1993 [3] Stock Performance - U S -listed shares of AstraZeneca fell more than 7% Tuesday to close at $66 27 [3] - The shares are down 1 6% in 2024 [3]

Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders.Piper Sandler initiated coverage on Upstream Bio with an Overweight rating and a price target of $75.William Blair has also initiated coverage of Upstream Bio with an Outp ...

The price could be right for these stocks.A low share price doesn't necessarily mean a stock is valued attractively. For example, you wouldn't invest in a company that markets oceanfront property in Arizona regardless of how low its share price was. However, prices per share can matter to investors who don't have a lot of cash to put to work.If you're in that group, you're in luck. Three Fool.com contributors have identified what they view as magnificent stocks trading at under $100 to buy in November. Here ...

Astrazeneca (AZN) closed at $71.42 in the latest trading session, marking a +0.38% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.41%. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 0.8%. Heading into today, shares of the pharmaceutical had lost 8.7% over the past month, lagging the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97% in that time. Investors will be eagerly watching for the performanc ...

In the latest trading session, Astrazeneca (AZN) closed at $75.05, marking a -1.12% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, added 0.56%. The pharmaceutical's stock has dropped by 2.92% in the past month, exceeding the Medical sector's loss of 4.4% and lagging the S&P 500's gain of 1.39%. The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming ...